Erastin analogue PRLX 93936

Drug Overview

Erastin analogue PRLX 93936 is an experimental medication designed to treat specific types of cancer that are often resistant to standard treatments. It is categorized as a Targeted Therapy and a “Smart Drug” because it focuses on a very specific weakness in cancer cells called “ferroptosis”—a unique form of iron-dependent cell death.

Unlike traditional chemotherapy that attacks all fast-growing cells, this drug is engineered to trigger a biological “shutdown” sequence only within the cancer cell. While it has been studied in clinical trials for patients with advanced tumors, it remains an investigational agent as researchers work to understand which patients will benefit the most.

• Generic Name: Erastin analogue PRLX 93936 (also known as Piperazine Erastin)
• US Brand Names: None (Currently an Investigational Drug)
• Drug Class: Ferroptosis Inducer; Small Molecule Inhibitor
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Not yet FDA-approved for general use)

What Is It and How Does It Work? (Mechanism of Action)

PRLX 93936 works through a process called ferroptosis. To understand this, imagine a cancer cell is like a high-tech factory. To stay running, the factory needs a cooling system to prevent “rust” (oxidative damage). PRLX 93936 effectively turns off that cooling system, causing the factory to overheat and self-destruct using its own iron supply.

At the molecular level, the drug follows a specific three-step pathway:

1. Inhibition of System  X_c^- : The drug blocks a transporter on the cell surface called System  X_c^- . This transporter is responsible for bringing an amino acid called cystine into the cell.
2. Glutathione Depletion: Cystine is the building block for Glutathione (GSH), the cell’s primary antioxidant. By blocking the transporter, PRLX 93936 starves the cell of GSH.
3. Lipid Peroxidation and VDAC Targeting: Without GSH, the cell cannot neutralize “lipid peroxides” (toxic fats). Additionally, the drug interacts with Voltage-Dependent Anion Channels (VDAC2/3) in the mitochondria. The result is a massive buildup of iron-dependent free radicals that destroy the cell membrane, leading to a specific type of cell death that doesn’t affect healthy cells in the same way.

FDA Approved Clinical Indications

As of early 2026, PRLX 93936 has not received final FDA approval for any specific disease. It is currently being utilized strictly within research settings and clinical trials.

Oncological Uses (Investigational):

• RAS-Mutated Cancers: Research has focused on tumors with  RAS  gene mutations (often found in lung, colon, and pancreatic cancers).
• Advanced Solid Tumors: Studied in patients whose cancer has returned after standard chemotherapy.
• Refractory Lymphoma: Evaluated for certain types of blood cancers.

Non-oncological Uses:

• There are currently no non-cancer uses for this medication.

Dosage and Administration Protocols

Because PRLX 93936 is an investigational drug, the exact dosage is determined by the specific clinical trial protocol. It is administered in a hospital or clinic setting under strict supervision.

Dose Adjustments:

• Hepatic/Renal Insufficiency: In early trials, patients with significant liver or kidney damage were typically excluded. If used, doses are adjusted based on creatinine clearance CrCl and liver enzyme levels (ALT/AST).

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has explored the safety and preliminary effectiveness of this drug, particularly when used alongside other therapies.

• Disease Stability: In Phase I/II trials, a subset of patients with advanced solid tumors achieved “Stable Disease,” meaning the cancer stopped growing for a period of several months.
• Biomarker Success: Research indicates that tumors with high levels of iron-regulating proteins are more sensitive to PRLX 93936.
• Combination Potential: Laboratory data from 2024 suggests that PRLX 93936 may make traditional chemotherapy work better by “priming” the cancer cells to die more easily. However, large-scale survival rate percentages (such as 5-year survival) are not yet available because the drug is still in early testing phases.

Safety Profile and Side Effects

As a targeted therapy, PRLX 93936 aims to be less toxic than standard chemo, but it does have specific side effects associated with the ferroptosis process.

Black Box Warning:

• None. (Investigational drugs do not receive formal Black Box Warnings until they are fully approved by the FDA).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Nausea: Mild stomach upset after infusion.
• Infusion Site Reactions: Redness or soreness where the IV was placed.
• Anorexia: Temporary loss of appetite.

Serious Adverse Events

• Hematologic Changes: Potential drops in white blood cell counts, which can increase infection risk.
• Electrolyte Imbalance: Changes in salt and mineral levels in the blood.
• Liver Stress: Temporary rises in liver enzymes.

Management Strategies: Doctors use “pre-medications” to prevent nausea and perform frequent blood tests to monitor organ function. If side effects become too strong, the dose is paused to allow the body to recover.

Research Areas

In the 2025–2026 research landscape, PRLX 93936 is being studied as a partner for Immunotherapy. Scientists believe that triggering ferroptosis in a tumor makes the “neighborhood” around the cancer more visible to the immune system. There is also emerging interest in using ferroptosis in Regenerative Medicine research to understand how to protect healthy stem cells while specifically killing cancer-causing stem cells.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Genetic Testing: To check for  RAS  mutations or specific iron-related markers.
• Baseline Blood Work: Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC).
• Imaging: CT or PET scans to measure the size of the tumor before starting.

Precautions During Treatment:

• Monitor for Fever: Since the drug can affect white blood cells, any fever should be reported immediately.
• Stay Hydrated: Drinking plenty of water helps the kidneys process the breakdown of cancer cells.

“Do’s and Don’ts”:

• DO keep a diary of any new symptoms, even if they seem minor.
• DO tell your doctor about all vitamins and supplements you take, especially antioxidants like Vitamin E, as they may interfere with the drug’s “rusting” mechanism.
• DON’T skip scheduled blood tests; these are vital for your safety.
• DON’T drive yourself home after the first few infusions until you know how the drug affects your energy levels.

Legal Disclaimer

The information provided in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Erastin analogue PRLX 93936 is an investigational drug and is not available for general use outside of authorized clinical trials. Always seek the advice of a qualified oncologist or healthcare provider regarding any medical condition. If you are experiencing a medical emergency, contact your local emergency services immediately.